

## CURRENT REPORT 29/2022

December 7, 2022

### Approval of the prospectus of the Company

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Issuer", "Company") informs that on December 7, 2022 the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego) issued a decision on the approval of the prospectus of the Company drawn up in connection with the public offering of up to 4,764,674 new Series J ordinary bearer shares with a nominal value of PLN 0.40 ("Series J Shares") and the intention to apply for admission of Series J Shares to trading on the regulated market of the Warsaw Stock Exchange S.A.

The prospectus will be published on December 7, 2022 on the Issuer's website at: <https://ryvu.com/pl/spo/>.

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board